Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 6/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MOGAT2 | Q3SYC2 | 7/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5629084 | 0.90 | SMN1; SMN2 (0.47) | HTR7TP53TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL5632368 | 0.89 | ATM (0.43) | HTR7TP53TSHRMOGAT2SMN1; SMN2 | |
| SCHEMBL5628430 | 0.87 | HTR7 (0.42) | HTR7MOGAT2 | |
| SCHEMBL3752809 | 0.85 | MAPT (0.47) | HTR7ALDH1A1 | |
| SCHEMBL5630601 | 0.85 | HTR7 (0.45) | HTR7TP53TSHRALDH1A1 | |
| SCHEMBL5629574 | 0.85 | MCHR1 (0.44) | TP53TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL14947355 | 0.85 | TSHR (0.45) | HTR7TP53TSHRALDH1A1 | |
| SCHEMBL1241268 | 0.84 | HRH3 (0.46) | HTR7TP53TSHRALDH1A1MOGAT2 | |
| SCHEMBL2400927 | 0.84 | HRH3 (0.46) | HTR7TP53TSHRALDH1A1MOGAT2 | |
| Water SCHEMBL16161850 | 0.83 | HRH3 (0.46) | HTR7TP53TSHRALDH1A1MOGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-05-10 | — | — | US | claimed |
| CN-1956962-B | Tetrahydroisoquinoline sulfonamide derivatives, their preparation and their use in therapy | SANOFI AVENTIS | 2014-08-20 | — | — | CN | disclosed |
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | BACE1, SLC6A2, KCNQ2 | HTR7 175/4885TP53 4291/4885TSHR 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.